Eltrombopag and Romiplostim Therapies Emerging as Effective Second-Line Chronic Immune Thrombocytopenia Treatment | FMI Predicts Korea to Remain a Key Revenue Generation Market
Future Market Insights in its latest report predicts Korea Thrombocytopenia Treatment Market to progress at around 3.5% to